Liminatus Pharma shares surge 12.30% after-hours following $30M equity investment MOU with Capital Trust Group.

Liminatus Pharma, Inc. (NASDAQ: LIMN) surged 12.30% in after-hours trading following the announcement of a memorandum of understanding (MOU) with Capital Trust Group for a $30 million equity investment via an earn-out mechanism and future strategic cooperation. The agreement, disclosed 27 days prior, marks a significant capital inflow and strategic partnership, likely boosting investor confidence in the company’s financial stability and growth prospects. Earlier news about the firm’s exploration of blockchain-linked capital strategies, while notable, predates the recent MOU and may not directly correlate with the immediate price reaction. The after-hours rally aligns with the positive implications of the equity deal, positioning Liminatus for potential operational expansion or debt reduction.